Skip to main content
Premium Trial:

Request an Annual Quote

908 Devices Prices $100M Public Offering

NEW YORK – Mass spectrometry firm 908 Devices said after the close of the market Wednesday that it has priced a public offering of 3,150,000 shares of its common stock at $32.00 per share.

Gross proceeds from the offering are estimated to be approximately $100.8 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on Nov. 15.

Cowen and SVB Leerink are the lead bookrunning managers for the offering, with William Blair and Stifel also acting as bookrunning managers.

908 Devices' core technologies include microfluidic capillary-electrophoresis systems for upfront separation of samples and high-pressure mass spec analyzers that are able to operate without the vacuum conditions used in conventional systems, allowing for much smaller and cheaper instruments. The Boston-based company went public in a $130 million initial public offering in December 2020.

In Thursday afternoon trading on the Nasdaq, 908 Devices shares were down less than 1 percent to $32.21.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.